SPMED
SPMED is a Korean precision medicine company offering pharmacogenomic testing kits, a PDSS clinical decision support platform, human recombinant CYP/UGT enzymes, and non-clinical ADME CRO services to hospitals, pharmaceutical companies, and international research customers.
- Company typePrivate
- Founded2016
- HeadquartersBusan, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What SPMED does
SPMED (주)에스피메드, SPMED Co., Ltd.) is a Busan-based Korean precision medicine company founded in 2016 that operates two integrated business lines: (1) clinical pharmacogenomics testing and genotyping kits for hospitals and healthcare providers, and (2) non-clinical ADME (absorption, distribution, metabolism, excretion) contract research services for pharmaceutical and biotech customers. The clinical line includes SPMED™ Genotyping Kit: CYP2D6 (CE-IVDD certified, KGMP/ISO 13485 manufactured), the SPMED PGx Test Panel covering genes such as CYP2C9, CYP2C19, CYP2D6, VKORC1, TPMT, HLA-B, and UGT1A1, and the PDSS (Personalized precision medicine clinical Decision Support System) platform delivered via web (pcdss.spmed.kr) and the MyDrugGene PDSS mobile app. The non-clinical line includes SPMED™ Human Recombinant Enzymes (CYP, UGT, FMO, CES, MAO, NAT) produced via baculovirus expression, plus in vitro ADME panels covering drug-drug interaction, transporter studies, enzyme inhibition/induction, BCS-biowaiver, and bioanalytical services.
The company monetizes through professional services (PGx testing fees billed via online service requests with monthly billing for long-term contracts, and project-based non-clinical CRO engagements) and product sales (genotyping kits and recombinant enzyme reagents). It serves a network of 100+ affiliated Korean hospitals including Seoul National University, Yonsei Severance, and Samsung Medical Center; Korean pharmaceutical companies such as Daewoong Pharmaceutical (which named SPMED '2025 Best CRO'); and international customers reached through the Korea Public Procurement Service Export-Led Pilot Purchase Program (Indonesia, Vietnam), ADMESCOPE in Finland, and exports to China. Go-to-market blends enterprise field sales through hospital affiliations, event-driven outreach at international scientific conferences (ISSX 2025, KSNT 2025), and government-channel export partnerships.
SPMED is privately held (backed by Korea Investment Partners, IMM Investment, and Time Folio through a Pre-A in April 2020 and Series A in September 2021), headquartered in Busan's Eco Delta City with a Seoul sales/marketing office, and holds CE-IVDD, ISO 13485:2016, GMP, KGMP, and Genetic Testing Agency certifications. Pricing is quote-based across all four revenue streams and not publicly disclosed.
SPMED firmographics
Firmographics- Name
- SPMED
- Legal name
- (주)에스피메드
- Website
- https://spmed.kr
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SPMED is a Korean precision medicine company offering pharmacogenomic testing kits, a PDSS clinical decision support platform, human recombinant CYP/UGT enzymes, and non-clinical ADME CRO services to hospitals, pharmaceutical companies, and international research customers.
- Ownership category
- akta.pro rank
SPMED industry classification
Industry- Product category
- Precision Medicine Diagnostics & CRO
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- DMPK / ADME & Bioanalysis (HLAGAFAC)
- akta.pro secondary industries
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)
Keywords
Where SPMED is headquartered
LocationHeadquarters
- HQ city
- Busan
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
SPMED business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Pharmacogenomics Testing Services: Laboratory testing services for drug-gene interactions provided to affiliated hospitals and medical institutions. Test results are delivered via PDF report after online login.
- SPMED™ Genotyping Kit Sales: Sale of in vitro diagnostic kits including SPMED™ Genotyping Kit: CYP2D6 for pharmacogenetic testing. CE-IVDD certified product exported to international markets.
- Human Recombinant Enzyme Products: Sale of human recombinant metabolizing enzymes (CYPs, UGTs, FMOs) for use in new drug development and pharmaceutical research. Exported to Northern Europe (Finland), China, and other markets.
- Non-Clinical CRO Services: Contract research organization services for preclinical drug development including ADME assessments, DDI studies, and pharmacokinetics support for pharmaceutical companies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Monthly | Custom pharmacogenomics testing services |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
SPMED product offering
Product offeringCore offering
SPMED provides pharmacogenomics-based personalized medicine services, including PGx testing services and CE-IVDD certified SPMED™ Genotyping Kits (e.g., CYP2D6), supported by the PDSS clinical decision support platform. The company also operates a non-clinical CRO business offering in vitro ADME testing services (DDI, permeability, transporter, BCS-biowaiver studies) and manufactures high-quality human recombinant metabolic enzymes (CYPs, UGTs, FMOs) for pharmaceutical and biotech research customers.
Product overview
SPMED operates as a pharmacogenomics and preclinical CRO services company offering two core product lines: (1) Personalized Medicine solutions including SPMED™ Genotyping Kits for pharmacogenetic testing (CYP2D6, CYP2C9, CYP2C19, VKORC1, TPMT, HLA-B, UGT1A1 and other genes), PDSS (Personalized precision medicine clinical Decision Support System), and related mobile applications; (2) Non-Clinical ADME services including SPMED™ Human Recombinant Enzymes (Cytochrome P450 and UGT enzymes), in vitro ADME testing panels, drug-drug interaction studies, and bioanalytical services. The company serves pharmaceutical companies, biotech firms, healthcare providers, and research institutions with integrated solutions spanning from genetic testing to preclinical drug development support.
Differentiator
Problem solved
Functional benefit
Brands
- PDSS: Personalized precision medicine clinical Decision Support System - an IT platform that applies individual test results for precision medicine treatment
- SPMED™ Genotyping Kit
- SPMED™ Human Recombinant Enzymes
- MyDrugGene PDSS
Products and services
- SPMED™ Genotyping Kit: CYP2D6 In vitro diagnostic kit for detecting CYP2D6 gene variations that affect drug metabolism, enabling personalized drug prescriptions based on individual genetic profiles. CE-IVDD certified and approved for clinical use in Korea.
- SPMED PGx Test Panel Pharmacogenomics testing service covering multiple drug metabolism genes including CYP2C9, CYP2C19, CYP2D6, VKORC1, TPMT, HLA-B, and UGT1A1, with related drugs documented for each gene test. Delivered to hospitals and healthcare providers.
- SPMED PGx-Premium Test Comprehensive pharmacogenomic test covering drugs for diabetes, arteriosclerosis, arrhythmia, peptic ulcer, gout, antipyretic, analgesic, anti-inflammatory, blood pressure lowering, blood coagulation inhibitor, and antimalignant conditions.
- SPMED PGx-Standard Test Standard pharmacogenomic test covering arteriosclerotic agents, peptic ulcer solutions, antipyretic, analgesic, anti-inflammatory agents, blood pressure lowering agents, blood coagulation inhibitors, and antimalignant tumor agents.
- SPMED PGx-SCAR Test Specialized pharmacogenomic test focusing on antiviral drugs, gout drugs, and anti-epileptic drugs for specific therapeutic area applications.
- PDSS (Personalized precision medicine clinical Decision Support System) IT platform implementing personalized precision medicine that applies drug dosage algorithms, risk prediction, and non-genetic factors to provide individualized medication guidance based on pharmacogenetic test results.
- MyDrugGene PDSS Personalized drug prescription service platform providing pharmacogenetic-based precision medicine guidance for individual patients.
- My Data SPMED Mobile Application Mobile application enabling patients and providers to access and manage pharmacogenetic test results and personalized medicine information.
- SPMED™ Human Recombinant Enzymes Recombinant human metabolic enzymes (Cytochrome P450, UGT, FMO, CES, MAO, NAT enzymes) expressed using baculovirus system for preclinical ADME testing, drug metabolism studies, and pharmaceutical research. Exported to Northern Europe, China, and other markets.
- Non-Clinical ADME Testing Services Comprehensive in vitro ADME services including Initial ADME Panel, DDI Panel, Peptide Panel, permeability studies, protein binding, metabolism studies, transporter studies, enzyme inhibition/induction assays, BCS-Biowaiver, and bioanalytical services following FDA recommendations.
Quantifiable outcome
- Achieved '2025 Best CRO' recognition from Daewoong Pharmaceutical's New Drug Center
- +2 more outcomes
Companies that use SPMED
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
SPMED technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
SPMED partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- ADMESCOPE (Finland)minorFirst recombinant proteinase export customer to Northern Europe (Finland). ADMESCOPE distributes SPMED's human recombinant enzyme products in the European market.
- IlluminacoreSigning of business agreement for joint research and mutual cooperation in 2020. Illumina is a global leader in DNA sequencing and array-based technologies.
- Isam Hospital and Busan Adventist HospitalminorHospital designation agreements for pharmacogenomic testing services, enabling patient referrals and testing services through hospital networks.
- Next&BiocoreMOU signing for organoid-based ADME evaluation platform development. Partnership aimed at creating innovative preclinical evaluation solutions combining SPMED's ADME expertise with Next&Bio's organoid technology.
Scale indicators4 records
Recent moves9 records
Expansion highlights5 records
SPMED competitors and assessment
Company assessmentBroad incumbents
- Eurofins Discovery: Global CRO division of Eurofins offering in vitro ADME, DDI, and drug metabolism services including recombinant enzymes — directly competes with SPMED's ADME CRO and recombinant enzyme product lines at significantly greater scale.
- Seegene: Larger Korean molecular diagnostics company developing PCR-based IVD kits and exporting globally — overlaps with SPMED's genotyping kit and IVD export business but operates at significantly greater scale across broader infectious disease and oncology menus.
- LabCorp Drug Development (formerly Covance): Global central lab and CRO offering bioanalytical, ADME, and clinical trial laboratory services — overlaps with SPMED's preclinical ADME and bioanalytical offerings for global pharma clients.
- Charles River Laboratories: Global preclinical CRO offering DMPK, ADME, and bioanalytical services to pharma R&D — competes head-to-head with SPMED's non-clinical ADME business for Korean and global pharma budgets.
- Bioneer: Korean molecular diagnostics and life science tools company developing PCR-based IVD kits, reagents, and instruments — comparable in IVD product structure and Korean export ambitions to SPMED's genotyping kit business.
Direct peers
- Macrogen: Korean-headquartered genomics services and precision medicine company offering DNA sequencing, PGx, and molecular diagnostics to hospitals and pharma — directly comparable in Korean genomics market positioning and customer base to SPMED.
- OneOme: PGx testing and clinical decision support company offering RightMed test and integrated interpretive reports — directly comparable business model to SPMED's PGx testing + PDSS clinical decision support platform.
- SOLVO Biotechnology: Specialized transporter and ADME CRO offering in vitro drug transporter, metabolism, and recombinant enzyme services — closely comparable in scale and specialization to SPMED's ADME services and human recombinant enzyme catalog.
Emerging players
- XD Biosciences: Emerging ADME and recombinant enzyme provider focused on drug metabolism and transporter research — comparable in technical offering and emerging-player positioning to SPMED's ADME and recombinant enzyme lines.
Regional players
- Genomedia: Korean molecular diagnostics and PGx laboratory serving Korean hospitals — directly comparable to SPMED's domestic hospital-network PGx testing services within the same geography.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
SPMED social profiles
Digital presenceSPMED compliance and trust
Trust signalCompliance10 records
SPMED financial estimates
Financial estimateRevenue estimate
Valuation estimate
SPMED leadership team
Management profileNumber of profiles
Profiles1 record
SPMED funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SPMED M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SPMED
What does SPMED do?
SPMED provides pharmacogenomics-based personalized medicine services, including PGx testing services and CE-IVDD certified SPMED™ Genotyping Kits (e.g., CYP2D6), supported by the PDSS clinical decision support platform. The company also operates a non-clinical CRO business offering in vitro ADME testing services (DDI, permeability, transporter, BCS-biowaiver studies) and manufactures high-quality human recombinant metabolic enzymes (CYPs, UGTs, FMOs) for pharmaceutical and biotech research customers.
Is SPMED a public or private company?
SPMED is a private company. It is classified as venture growth investor backed and is currently operating.
When was SPMED founded?
SPMED was founded in 2016. It employs 11 to 50 people.
Where is SPMED based?
SPMED is headquartered in Busan, South Korea, in the Asia region.
How does SPMED make money?
Four revenue lines are on record. Pharmacogenomics Testing Services are the primary driver. The others are SPMED™ Genotyping Kit Sales, human Recombinant Enzyme Products and non-Clinical CRO Services.
Who are SPMED's main competitors?
Broad incumbents on record are Eurofins Discovery, Seegene, LabCorp Drug Development (formerly Covance), Charles River Laboratories and Bioneer. Direct peers are Macrogen, OneOme and SOLVO Biotechnology. XD Biosciences is listed as an emerging player. Genomedia is listed as a regional player.
Does SPMED have an API?
No public API is recorded for SPMED.
What industry is SPMED in?
SPMED's product category is Precision Medicine Diagnostics & CRO. Its primary akta.pro industry code is HLAGAFAC, DMPK / ADME & Bioanalysis, with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 325413 and its SIC code is 2835.